by Stephen Levin
For many years, women were forced to take a backseat to men when it came to medical science and treatment....
Conceptus' Re-Birth: Surviving in Women's Health
The early-to-mid 1990s marked the rise of a huge wave of interest in women's health among device start-ups and investors. Several women's health companies, including Conceptus, were among the ill-fated IPO Class of 1996 that largely failed to meet investor expectations. Most of these start-ups are no longer around, but Conceptus re-trenched and shifted its emphasis from fertility to a new approach to sterilization, which finally received FDA clearance late last year. The company has survived the pitfalls that derailed other women's health start-ups, most notably a customer group that is difficult to access and slow to adopt new technology, and a challenging reimbursement environment, but in doing so, may be the exception that proves the rule.
More from Business Strategy
• By
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
• By
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
• By
Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.
• By
Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.
More from In Vivo
• By
New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.
• By
The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.
• By
Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.